ROCKVILLE, MD and SHENZHEN, CHINA, October 11, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a biopharmaceutical company developing novel multifunctional multi-targeted therapies for metabolic and digestive diseases

HighTide Therapeutics, Inc. (“HighTide”) was invited to present at the Office for Attracting Strategic Enterprises (OASES) launching ceremony hosted by the Hong Kong government. HighTide, a company focused on the discovery and development o

ROCKVILLE, MD and SHENZHEN, CHINA, October 3rd, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that the primary findings from the Phase 2 clinical trial of berberine ursodeoxycholate (HTD1801)

Leadership of the UK Chinese Business Association (UKCBA), including chairman, Mr. Jinlong Zhang, and secretary-general and executive vice chairman, Mr. Jie Yin, along with the UK delegation, visited HighTide Therapeutics, Inc.

ROCKVILLE, MD and SHENZHEN, CHINA, June 24, 2023— HighTide Therapeutics, Inc. (“HighTide”) announces that data from the Phase 2a clinical trial of HTD1801, a first-in-class gut-liver anti-inflammatory metabolic modulator for patients with nonalcoholic

ROCKVILLE, MD and SHENZHEN, CHINA, May 15, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated biopharmaceutical company specializing in the discovery and development of first-in-class multifunctional therapies for metabolic and digestive